Alere Inc., the company that's in a contentious $5.8 billion deal to be acquired by Abbott Laboratories, rose the most since the day the offer was announced after it submitted partial financial results for 2015 to U.S. securities regulators, more than four months after delaying the annual report. The filing to the Securities and Exchange Commission fell short of all the details normally found in a 10-K.
↧